Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel Maintenance in Advanced Ovarian Cancer
NCT00003120Phase 3Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 1997
- Primary completion
- Jun 2003
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Paclitaxel Micelles for Injection in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoints: Progression-Free Survival and Overall Survival. Started Nov 1997; status: completed.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00003120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003120.